Roivant Sciences

Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases

Retrieved on: 
Thursday, December 1, 2022

The Vant has the exclusive option to collaborate with Pfizer on a next-generation TL1A directed antibody which recently entered Phase 1.

Key Points: 
  • The Vant has the exclusive option to collaborate with Pfizer on a next-generation TL1A directed antibody which recently entered Phase 1.
  • As such, RVT-3101 has the potential to provide greater efficacy by hitting multiple inflammatory pathways as well as fibrotic pathways.
  • We are excited about this collaboration with Pfizer on a potential first-in-class program, which we intend to pursue in both ulcerative colitis and in additional inflammatory and fibrotic diseases.
  • It is estimated that up to 2 million US adults suffer from inflammatory bowel diseases, which include ulcerative colitis and Crohns disease.

SK Biopharmaceuticals Names Donghoon Lee, Head of Bio Investment Center of SK Inc., as New CEO

Retrieved on: 
Thursday, December 1, 2022

PANGYO, South Korea, Nov. 30, 2022 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global pharmaceutical company, announced that it has named Mr. Donghoon Lee, Executive Vice President and Head of Bio Investment Center of SK Inc., as the new Chief Executive Officer and President of SK Biopharmaceuticals and its U.S. subsidiary SK Life Science. Mr. Lee will take the helm at the two companies, effective January 1 2023.

Key Points: 
  • Mr. Lee will bring expertise in global new business development and deal-making to further spur the growth of SK Biopharmaceuticals.
  • Dr. Jeong Woo Cho, who had been the CEO of SK Biopharmaceuticals and SK Life Science since 2017, will serve as the President of Future Growth.
  • Also, Mr. Jonggil Choi, Vice President of Bio Investment Center of SK Inc., has been appointed as the Vice President of Global Strategy.
  • At SK Inc., Lee headed the Bio Investment Center, executing key investment deals in line with SK Group's vision to fortify battery, bio, and chip (BBC) businesses as its main growth drivers.

Roivant Social Ventures Publishes Global Access Scorecard to Guide Impact Investors in Making Equitable Investment Decisions

Retrieved on: 
Monday, November 28, 2022

NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Roivant Social Ventures (RSV), a social impact organization launched by Roivant Sciences, today announced the publication of a proprietary Global Access Scorecard that impact investors can use to guide equitable investment decisions.

Key Points: 
  • NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Roivant Social Ventures (RSV), a social impact organization launched by Roivant Sciences, today announced the publication of a proprietary Global Access Scorecard that impact investors can use to guide equitable investment decisions.
  • The innovative scorecard is designed to help impact investors identify investments that, in addition to meeting existing investment criteria, will expand inclusive access to healthcare.
  • The Global Access Scorecard uses building blocks of existing Environmental, Social, Governance (ESG) principles and applies them to the biotech, healthcare, and drug manufacturing context.
  • Roivant Social Ventures (RSV) is a 501(c)(3) social impact organization focused on improving healthcare access and outcomes for underserved groups.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPNT, WAFD, MYOV

Retrieved on: 
Sunday, November 27, 2022

If you are an Opiant shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Opiant shareholder, click here to learn more about your rights and options .
  • If you are a Washington shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AYLA, MYOV, USER, AGFS

Retrieved on: 
Sunday, November 20, 2022

If you are an Ayala shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Ayala shareholder, click here to learn more about your rights and options .
  • If you are a Myovant shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources

Retrieved on: 
Wednesday, November 16, 2022

BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources.

Key Points: 
  • BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources.
  • Beginning November 28, Ms. Tomlin will be responsible for developing talent solutions and human resources strategies across Myovants global functions.
  • "We are delighted to welcome Ann to Myovant during this exciting time of the companys growth," said David Marek, Chief Executive Officer of Myovant Sciences, Inc.
  • "I am thrilled to join Myovant at this pivotal time for the company," said Ms. Tomlin, Senior Vice President for Human Resources of Myovant Sciences, Inc. "Myovant has proven to be an industry leader through its science, successful product launches and commitment to patient-centered transformative advocacy.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FORG, IMRA, LFG, MYOV

Retrieved on: 
Sunday, November 13, 2022

If you are an Imara shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Imara shareholder, click here to learn more about your rights and options .
  • If you are an Archaea shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

bit.bio Expands Its Portfolio With Three New Human Cell Products for Research and Drug Discovery in Neurodegenerative and Neurological Diseases

Retrieved on: 
Wednesday, November 23, 2022

bit.bios cell products are reprogrammed from human induced pluripotent stem cells (hiPSCs) using the companys proprietary precision reprogramming technology opti-oxTM.

Key Points: 
  • bit.bios cell products are reprogrammed from human induced pluripotent stem cells (hiPSCs) using the companys proprietary precision reprogramming technology opti-oxTM.
  • These key features make the products ideally suited to screening applications for early drug discovery as well as for fundamental research.
  • Dr Farah Patell-Socha, VP Research Products at bit.bio, said:
    The launch of these products is further evidence of our robust CNS cell pipeline for research and drug discovery.
  • bit.bio is a synthetic biology company providing human cells for research, drug discovery and cell therapy.

Dermavant Launches First Commercial for VTAMA® (tapinarof) cream, 1% as Part of a National, Multimedia Campaign for Adults with Plaque Psoriasis

Retrieved on: 
Tuesday, November 22, 2022

Many have been waiting a long time for a different plaque psoriasis treatment like VTAMA cream.

Key Points: 
  • Many have been waiting a long time for a different plaque psoriasis treatment like VTAMA cream.
  • The commercial gives topical plaque psoriasis patients aka the silent majority a voice, empowering them to demand more from their topical plaque psoriasis treatment and truly feel heard.
  • Indication: VTAMA (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.
  • Plaque psoriasis, also called psoriasis vulgaris, is the most common form and affects about 80 to 90% of people with psoriasis.

Kinevant Sciences Announces First Patient Dosed in Phase 2 Study of Namilumab for the Treatment of Pulmonary Sarcoidosis (RESOLVE-Lung)

Retrieved on: 
Thursday, November 17, 2022

This Phase 2 clinical study will evaluate the efficacy and safety of Kinevants namilumab for the treatment of pulmonary sarcoidosis.

Key Points: 
  • This Phase 2 clinical study will evaluate the efficacy and safety of Kinevants namilumab for the treatment of pulmonary sarcoidosis.
  • The study will assess the efficacy and safety of namilumab in approximately 100 patients with pulmonary sarcoidosis across a 26-week treatment period.
  • All patients that complete the 26-week double-blind treatment period will be eligible to participate in a 28-week OLE treatment period on namilumab.
  • Kinevant is initially focusing on sarcoidosis with an anti-GM-CSF monoclonal antibody, namilumab, currently being evaluated in the Phase 2 RESOLVE-Lung study in patients with pulmonary sarcoidosis.